



# Research Tips

## University of Colorado Denver

Vice Chancellor for Research: RJ Traystman

12/15/2009

Volume 1 Issue 8

### Stimulus Funding Update (ARRA)

As of December 15, 2009, UCDenver has submitted 572 ARRA grants and received ARRA funding for a total of 112 ARRA awards funded at \$51,869,792.

### Office of Grants and Contracts


Got Contracts? Electronic contracts should be submitted to OGC.Contracts@ucdenver.edu. OGC needs electronic versions of contract documents in order to facilitate review and negotiation of contracts. Contracts are reviewed for compliance with University, State, and Federal policies, rules, and regulations. We have recently revised all of our subcontract templates. We hope to shorten our processing times with these changes. Please be sure to read the templates including our email instructions as you may be asked to follow new procedures. All correspondence should continue to be sent to OGC.Subcontracts@UCDenver.edu. Please feel free to contact Bernadine Sena 303-724-0092, Bernadine.Sena@UCDenver.edu, or Adelita DeHerrera 303-724-0091, Adelita.DeHerrera@UCDenver.edu directly for any questions.

### Biosafety

There has been an increase in incidents of improper disposal of regulated medical wastes, particularly with needles and other sharps, particularly at AMC, in recent weeks. This is a reminder that each of us has a responsibility for the proper segregation and disposal of regulated medical wastes. Sharps placed improperly in regular trash present an injury risk to our co-workers, students, facilities and housekeeping staff. All sharps and needles must be placed in rigid containers designated for the disposal of sharps and then placed into the regulated medical waste stream.

Improper disposal practices also present a risk of investigation and findings of violations by Colorado Dept. of Public Health and Environment and the U. S. Dept. of Transportation. Civil and criminal fines and penalties may be assessed by those agencies. Civil fines and penalties can be assessed at \$2,000 per day per incident by the state agency and \$5,200 per day per incident by the federal agency. If you have any further questions about proper disposal of needles and other sharps, or proper segregation and disposal of regulated medical wastes, please contact the Dept. of Environmental Health and Safety, Biosafety Office at 303-724-0235. Thank you for your attention to this important issue.

### Dr. T's Corner



#### Federal Spending on Academic Research Rose Slightly in 2008

Federal Spending on Academic Research Rose Slightly in 2008. Federal spending on scientific research at universities and colleges rose slightly in 2008, following two years of declines, but the federal share of total academic research spending again dropped. Over all, higher-education institutions reported research-and- development expenditures of \$51.9-billion in 2008, 2.3 percent more than the previous year in inflation-adjusted dollars. The federal government remained the largest source of such funds, providing \$31.2-billion in 2008, up from \$30.5-billion in 2007. But the figures show continuing erosion in the federal share of total spending, from 64 percent in 2005 to 60 percent last year. Institutions increased their own spending on research by 7 percent, to \$10.4-billion last year, and contributions by industry to academic research were also up by about 7 percent, to \$2.9-billion. Spending by state and local governments rose by almost 9 percent, to \$3.4-billion. The top 20 institutions reporting the largest total expenditures accounted for 30 percent of total research spending. Johns Hopkins University again was the leader in research spending, with its \$1.4-billion total including \$845-million in spending by its Applied Physics Laboratory. The NSF released a ranking of institutions by the amount of federal funds received.

Rank	Institution	Dollars (in thousands)	
		2007	2008
1	Johns Hopkins U.	\$1,362,836	\$1,425,100
2	U. of Washington	\$620,375	\$614,069
3	U. of Michigan (all campuses)	\$577,201	\$592,768
4	Stanford U.	\$534,787	\$509,477
5	Massachusetts Institute of Technology	\$476,318	\$495,008
6	U. of California at San Diego	\$475,708	\$490,963
7	U. of Pennsylvania	\$449,687	\$482,321
8	U. of Wisconsin at Madison	\$469,076	\$474,440
9	U. of California at San Francisco	\$467,402	\$472,642
10	U. of California at Los Angeles	\$488,846	\$471,932
11	Columbia U.	\$459,748	\$461,029
12	U. of Pittsburgh (all campuses)	\$441,357	\$456,172
13	Duke U.	\$459,122	\$451,317
14	U. of Colorado (all campuses)	\$442,303	\$437,393
15	Pennsylvania State U. (all campuses)	\$370,789	\$406,528
16	Washington U. St. Louis	\$424,451	\$393,918
17	Harvard U.	\$392,103	\$383,330
18	Yale U.	\$349,027	\$374,551
19	U. of North Carolina at Chapel Hill	\$346,672	\$373,098
20	U. of Minnesota (all campuses)	\$337,966	\$364,137

Source: National Science Foundation

## Profile: James Hageman, PhD

Jim Hageman is Associate Vice Chancellor for Research and has responsibilities for the newly formed Office of Research Development and Education (ORDE). ORDE serves all faculty on both campuses (DDC and AMC) to provide customized fund searching, grant preparation seminars, the ORDE newsletter and an up-to-date web site containing useful information for grant seekers.

He assists academic deans at DDC in developing and supporting research and creative agendas of faculty members, particularly those newly hired. Jim administers a number of internal seed grants designed to help faculty obtain grants and contracts, some as interdisciplinary efforts across campuses. He also provides staff support in launching new group efforts seeking grant support. In addition, he works closely with the Vice Chancellor for Research and other personnel in Research Administration to make the grant application process and compliance efforts between campuses as seamless as possible.

Prior to coming to UC Denver, Jim was Dean of the Graduate School and Vice Provost for Research at Central Michigan University, assisting faculty in increasing external funding, filing 12 patents on behalf of faculty, and initiating the successful formation of an interdisciplinary doctorate in the science of advanced materials. From 1971 - 2000 he was in the Department of Chemistry and Biochemistry at New Mexico State University, serving as head of department and was founding director of an interdisciplinary graduate program in molecular biology. His research work, funded by NIH, NSF and USDA, involved: microbial metabolism associated with sporulation, especially calmodulin like proteins, proteinases and protein turnover; characterization and attempts to domesticate *Salsola* species (tumbleweed); and synthesis and use of new boronic acids in chromatography. Jim and his wife Mary have two Labradors, enjoy their time with 10 grandchildren, and he rides his bike to work most days.



Jim Hageman, PhD

## COMIRB

Please note that for FDA regulated human subject research, the FDA has issued final guidance on "Investigator Responsibilities - Protecting the Rights, Safety, and Welfare of Study Subjects."

The goal of this guidance is to help investigators better meet their responsibilities with respect to protecting human subjects and ensuring the integrity of data from clinical investigations. This guidance is intended to clarify for investigators and sponsors FDA's expectations concerning the investigator's responsibility (1) to supervise a clinical study in which some study tasks are delegated to employees or colleagues of the investigator or other third parties and (2) to protect the rights, safety, and welfare of study subjects. The guidance document is now available from FDA's website using the following web link: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM187772.pdf>. Please cut and paste this address into your browser address window.

### Rederivation Update

Please contact the Transgenic and Gene Targeting Core immediately to schedule cryo-preservation/implantation of your unique mouse lines that will be transferred to R2. The Vice Chancellor for Research has set the end of December as the deadline for scheduling cryo-pervations. After the deadline has passed, you might be financially responsible for the rederivation of your lines. Please contact us immediately at [makeamouse@ucdenver.edu](mailto:makeamouse@ucdenver.edu) to schedule rederivations. Given that we schedule procedures several weeks ahead of time, you might not make the December deadline if you wait much longer. Please let us know if we can assist you in any way to facilitate the process.

### Environmental Health & Safety

Seasonal flu shots available (\$15). Call 303-724-0345 to schedule appointment.

### OLAR Reminder

Carts in RC1 - Starting December 15, 2009, we will be providing carts for investigators in RC1. No investigator carts will be allowed into the facility. Carts should be left in the front office area.

### Morphology and Phenotyping Core at UC Denver

The Morphology and Phenotyping Core is located in the Charles C. Gates Regenerative Medicine and Stem Cell Biology (RMSCB) Program and the Department of Dermatology at UC Denver. The objective of the Core is to provide investigators with the tools and expertise to process and analyze tissue samples. The Core specializes in processing skin/epithelial tissues, however, other tissues are also routinely processed. Core services include preparation of paraffin blocks, sectioning of paraffin and frozen blocks, and preparing basic histological stains. For a list of services and prices, please visit the website:

<http://www.uchsc.edu/stemcell/resources/histo.htm> or contact Dr. Maranke Koster ([Maranke.Koster@ucdenver.edu](mailto:Maranke.Koster@ucdenver.edu)). Please cut and paste the above link into your browser address window.

### IMPORTANT INFORMATION FOR RESEARCH WITH INFLUENZA VIRUSES AND GENES

NIH has recently revised the NIH Guidelines as they apply to recombinant experiments with influenza viruses that contain genes and/or segments from human H2N2 (1957-1968), HPAI H5N1, and 1918 H1N1 (e.g., chimeric viruses with reassorted segments generated by reverse genetics, viruses in which specific mutations are introduced). The new Section III-D-7 states: "Experiments with influenza viruses generated by recombinant methods (e.g., generation by reverse genetics of chimeric viruses with reassorted segments, introduction of specific mutations) shall be conducted at the biosafety level containment corresponding to the risk group of the virus that was the source of the majority of segments in the recombinant virus (e.g., experiments with viruses containing a majority of segments from a RG3 virus shall be conducted at BL3)." If you are conducting research with influenza viruses, or segments of influenza viruses, please be sure to consult with the Institutional Biosafety Committee (<http://www.uchsc.edu/safety/BioSafety/InstBioSafCommittee.htm>) and the Biosafety Office ([biosafety.program@ucdenver.edu](mailto:biosafety.program@ucdenver.edu)) to assure all appropriate compliance and containment measures are implemented. Please cut and paste the above link into your browser address window.